Halma PLC
Avatud
SektorTööstus
3,614 0.61
Ülevaade
Aktsiahinna muutus
24h
Min
3568
Max
3656
Sissetulek | -1.3M 186M |
|---|---|
Müük | 108M 1.3B |
P/E Sektori keskmine | 37.225 38.75 |
Aktsiakasum | 0.553 |
Dividenditootlus | 0.69 |
Kasumimarginaal | 13.793 |
Töötajad | 9,000 |
EBITDA | -2.5M 315M |
Dividenditootlus Sektori keskmine | 0.69% 2.12% |
|---|---|
Järgmine tulemuste avaldamine | 19. nov 2026 |
Turukapital | -4.3B 14B |
|---|---|
Eelmine avamishind | 3613.39 |
Eelmine sulgemishind | 3614 |
Uudiste sentiment
By Acuity
67%
33%
337 / 403 Pingereas Industrials
Halma PLC Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Halma PLC Prognoos
Sentiment
By Acuity
337 / 403 Pingereas Tööstus
Uudiste sentiment
Tõusu märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Halma PLC
Halma plc, together its subsidiaries, provides technology solutions in the safety, health, and environmental markets in the United States, Mainland Europe, the United Kingdom, the Asia Pacific, Africa, the Middle East, and internationally. It operates through three segments: Safety, Environmental & Analysis, and Healthcare. The Safety segment provides products that protect people, assets and infrastructure, and electrical systems which is used in public and commercial spaces and in industrial and logistics operations. This segment serves Fire Safety, Power Safety, Industrial Safety, and Urban Safety markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; environmental monitoring; analysis of air quality, gases, and water; detection of hazardous gases; and water analysis & treatment systems. It serves the optical analysis, water analysis and treatment, and environmental monitoring markets. The Healthcare segment provides components, devices and systems that provide information and analytics to understand patient health and make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable treatment across clinical specialties, as well as critical fluidic components used by medical diagnostics and original equipment manufacturers. This segment serves the life sciences, health assessment and analytics, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.